Skip to content
Review Open access

Adoptive cell therapy in lung cancer: progress, challenges, and prospects

Sep 2026 · Chinese Medical Journal - Pulmonary and Critical Care Medicine · Vol 4, pp. 235 - 249 · 0 citations · 124 references
Medicine

TL;DR

The current progress in cell therapy for lung cancer is summarized, key challenges are analyzed, and potential solutions are proposed.

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Over the past decade, immunotherapy, represented by immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1/programmed cell death protein ligand-1 (PD-1/PD-L1) or cytotoxic T lymphocyte associated antigen-4 (CTLA-4), has revolutionized the treatment paradigm of lung cancer, reducing the risk of death by approximately 30%. However, approximately 70% of patients with advanced non-small cell lung cancer are either non-responsive to ICIs or initially respond to treatment but eventually experience disease progression due to acquired resistance. This subset of non-responsive or ultimately resistant patients is often characterized by complete exhaustion of endogenous anti-tumor T cells, which are unable to exert anti-tumor effects, thereby leading to ICI non-response or resistance. Correspondingly, the adoptive transfer of immune cells has shown promising efficacy in numerous clinical studies involving this patient population. Nevertheless, the Food and Drug Administration (FDA) has not yet approved any cell therapy strategy for lung cancer, primarily because of factors such as the hostile tumor microenvironment and T cell exhaustion. Herein, we summarize the current progress in cell therapy for lung cancer, analyze key challenges, and propose potential solutions.

Read PDF

Similar papers

Review Open access Sep 2026

The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy

Evidence that agents capable of inducing ICD may instead promote cellular senescence when administered at lower concentrations for prolonged periods is highlighted, indicating that these distinct cellular outcomes can be determined by drug dose and treatment duration.

Seong-Ah Shin, Minji Kim, Moonsu Kim et al. · 0 citations
Review Open access Oct 2026

CAR-T Cell Therapy Combined with PD-1 Inhibitors in Cancer: Synergistic Antitumor Mechanisms, Clinical Progress, and Future Perspective

Data from preclinical models and clinical trials indicate that PD-1 inhibition helps exhausted CAR-T cells recover function, shifts the TME away from an immunosuppressive state, and supports epitope spreading; together these effects strengthen antitumor activity and may lower relapse rates.

Jia-Qi Hu · 0 citations
Review Open access Oct 2026

Immune Checkpoint Inhibitor Resistance in Genitourinary Cancers: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies

Overall, ICI resistance in GU cancers emerges as a multidimensional phenomenon with distinct biological drivers across tumor subtypes; precision combinations targeting both intrinsic tumor factors and the immunosuppressive TME represent the most promising avenue to overcome resistance, and standardization of composite...

A. Chaux · 0 citations
Review Open access Oct 2026

Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery

Lung cancer is the leading cause of cancer death, characterized by high mortality rates, tumor adaptation and heterogeneity, and immune evasion mechanisms. Despite recent advancements in chemotherapy, radiation, and surgery, survival rates for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain...

Lu-Ke Ding, Anna Staskiewicz, Jesse Kao et al. · 0 citations
Sep 2026

FasL-mediated death of activated intratumoral T cells drives secondary resistance to cancer immunotherapy.

Cancer progression following an initial response to immunotherapy (secondary resistance; 2°R) is a major and poorly understood problem. We treated mice bearing B16 melanoma with a combination of a regulatory T cell (Treg) depleting, non-IL-2 blocking antibody (anti-CD25NIB) and an autologous cancer cell vaccine (GVAX)....

Chen Qing, E. Ghorani, K. Foster et al. · 0 citations
Review Open access Oct 2026

Immunotherapy Resistance in Small Cell Lung Cancer: Mechanisms and Therapeutic Vulnerabilities

This review examines lineage plasticity, epigenetic regulation, defective antigen presentation, defective antigen presentation, and altered DNA sensing and interferon responses that interact with T-cell dysfunction, suppressive myeloid populations, and organ-specific niches.

Li-Wen Xu, Yi-Xuan Cheng, Han-Rui Chen et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.